Keywords: Genfit, GFT505, Hepatititis, NASH, USA, FDA, Ph IIb

FDA approves initiation of a Phase IIb study of Genfit's GFT505

Article | 05 September 2012

Print This

French biotech firm Genfit (Alternext: ALGFT) says that the US Food and Drug Administration has approved the continuing development of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in